Table 1 Demographic and clinical characteristics of 62 visits
Age (years): mean ± SD | 14.09 ± 5.30 |
Gender: female/male | 40/22 |
JIA subtype: n (%) | |
 Oligoarthritis | 24 (38.7%) |
 Polyarthritis | 29 (46.8%) |
 ERA | 9 (14.5%) |
Selected indicator joint: n (%) | |
 Knee | 27 (43.5%) |
 Wrist | 18 (29%) |
 Elbow | 8 (12.9%) |
 Ankle | 6 (9.7%) |
 Finger | 2 (3.2%) |
 Toe | 1 (1.6%) |
Treatment: n (%) | |
 NSAIDs | 29 (46.7%) |
 DMARDs: | 35 (56.5%) |
  Methotrexate | 33 (53.2%) |
  Sulfasalazine | 1 (1.6%) |
  Azathioprine | 1 (1.6%) |
 Biologics: | 35 (56.5%) |
  Etanercept | 17 (27.4%) |
  Adalimumab | 16 (25.8%) |
  Tocilizumab | 2 (3.2%) |